WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 6 fonti

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Raccontata da

morningstar.com

medpagetoday.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo6 h fa

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Timeline cronologica

sabato 6 giugno 2026·morningstar.com
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
sabato 6 giugno 2026·healio.com
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented…

6 h fa

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

Leggi questa versione → originale

france24.com59 min fa

Encouraging trial results for AstraZeneca's new weight-loss pill

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1 oral drugs, trial results showed Monday.

Leggi questa versione → originale

healio.com3 g fa

Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes

NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented at the American Diabetes Association…

Leggi questa versione → originale

medpagetoday.com16 h fa

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

Less frequent dosing could support better long-term adherence, says researcher

Leggi questa versione → originale

elnuevodia.com4 h fa

Una nueva pastilla de GLP-1 demuestra su eficacia frente a la diabetes y el sobrepeso

Hasta la fecha, las terapias con GLP-1 se han limitado a formulaciones inyectables u orales, cada una con sus propias limitaciones en cuanto a la administración y la dosificación

Leggi questa versione → originale

sabato 6 giugno 2026·

morningstar.com

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

sabato 6 giugno 2026·

morningstar.com

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

domenica 7 giugno 2026·

morningstar.com

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

domenica 7 giugno 2026·

morningstar.com

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

lunedì 8 giugno 2026·

medpagetoday.com

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

Less frequent dosing could support better long-term adherence, says researcher

lunedì 8 giugno 2026·

morningstar.com

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

lunedì 8 giugno 2026·

statnews.com

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

martedì 9 giugno 2026·

elnuevodia.com

Una nueva pastilla de GLP-1 demuestra su eficacia frente a la diabetes y el sobrepeso

Hasta la fecha, las terapias con GLP-1 se han limitado a formulaciones inyectables u orales, cada una con sus propias limitaciones en cuanto a la administración y la dosificación

martedì 9 giugno 2026·

france24.com

Encouraging trial results for AstraZeneca's new weight-loss pill

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1 oral drugs, trial results showed Monday.